Business Wire

NY-SULLIVAN-&-CROMWELL

Share
Robert J. Giuffra, Jr. and Scott Miller Become Co-Chairs of Sullivan & Cromwell LLP

Sullivan & Cromwell LLP announced today that Robert J. Giuffra, Jr. and Scott Miller have become Co-Chairs of the firm, effective January 1, 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220103005204/en/

Mr. Giuffra and Mr. Miller have served as Vice Chairs of the firm since January 2021. They succeed Joseph C. Shenker, the firm’s Chair since 2010, who will continue to serve on the firm’s Management Committee as Senior Chair in addition to continuing with his active client practice.

“Since the days of our founders, Sullivan & Cromwell has an unwavering commitment to our clients, our people and our communities,” said Mr. Shenker. “Bob and Scott exemplify these qualities, long ago establishing themselves as trusted counselors whose complementary strengths in litigation and corporate law reflect the broad scope of work we do for our clients around the world.”

“Our firm’s international practice and ability to deliver integrated client service through our network of 13 offices across four continents are critical to our success,” said Mr. Miller. “More than half of our firm’s clients are headquartered outside the United States, and Bob and I have each spent our careers handling our clients’ most complex cross-border matters. As the world becomes even more integrated and the issues clients face become more complex, we expect our global practice to be a driver of our firm’s continued success.”

“I am honored to work with Scott and our partners to build on our firm’s strong culture of excellence, innovation and commitment to our clients and each other,” said Mr. Giuffra. “For 143 years, our model has been tried and true: to recruit and train the best lawyers to work together to help our clients solve their most critical challenges and capture their highest value opportunities.”

Mr. Giuffra, a nationally prominent litigator, joined S&C in 1989 after serving as a law clerk to Chief Justice William Rehnquist of the U.S. Supreme Court and Judge Ralph Winter of the U.S. Court of Appeals for the Second Circuit. Based in New York, he has been a member of Sullivan & Cromwell’s Management Committee since 2007. A fellow of the American College of Trial Lawyers and International Academy of Trial Lawyers, he has successfully represented the firm’s clients in multi-billion dollar trials, litigations and government investigations. He has played a significant role in navigating some of the biggest corporate crises of the past 20 years, including the bankruptcy of Enron, the accounting frauds at Computer Associates and HealthSouth Corporation, the financial crisis, and the Volkswagen diesel emissions crisis for which he served as the carmaker’s national coordinating counsel. His current clients include Allianz, Goldman Sachs, Stellantis, UBS and Volkswagen. He has represented corporate boards and directors, CEOs, senior public officials, prominent families, law firms and professional sports teams.

Mr. Miller, a premier corporate counselor, joined S&C in 1986 after serving as a law clerk to Judge William A. Norris of the U.S. Court of Appeals for the Ninth Circuit. He routinely handles multi-billion dollar M&A, capital markets and other strategic transactions, internal and government investigations and other corporate crises. Now based in New York, he has been a member of the Firm’s Management Committee since 2014 and coordinates our U.S. and European corporate practices. He has worked on M&A and securities transactions in more than 20 countries, including the first privatization in Italy and the first German LBO. He represented Fiat Chrysler in its $60 billion merger with Peugeot, which transformed the global auto industry through the creation of Stellantis. Earlier, he represented Fiat in connection with its 2009 rescue of Chrysler, Ferrari in its 2015 IPO, and Alcan in fighting off a hostile takeover offer from Alcoa and in its $46 billion acquisition by Rio Tinto. He has represented DISH Network for two decades and recently in a series of transactions that helped it form and fund its nationwide wireless communications network. He has also recently been in the forefront of the SPAC market, representing among others DraftKings in its de-SPAC listing and other acquisitions and financings to create one of the world’s largest digital sports entertainment and gaming companies and Ermenegildo Zegna Group in its merger with a SPAC sponsored by Investindustrial through which Zegna became a NYSE-listed company, with an initial market capitalization in excess of $3 billion.

Mr. Giuffra is a graduate of Princeton University and Yale Law School. He has served as Chief Counsel of the U.S. Senate Banking Committee and as President of the Federal Bar Council. He is a member of New York’s Permanent Commission on Access to Justice and the Standing Committee on Rules of Practice and Procedure of the U.S. Courts. He is chair of the American Swiss Foundation.

Mr. Miller is a graduate of Arizona State University and Columbia Law School. He was managing partner of Sullivan & Cromwell’s Palo Alto office and has been resident in the firm’s London and Los Angeles offices. He is a trustee of the United States Council for International Business.

About Sullivan & Cromwell LLP

Sullivan & Cromwell LLP is a global law firm that advises on significant litigation, corporate investigations and complex regulatory, major domestic and cross-border M&A, finance, corporate and restructuring transactions, tax and estate planning matters. Founded in 1879, Sullivan & Cromwell has approximately 900 lawyers located in offices in New York, Washington, Los Angeles, Palo Alto, London, Frankfurt, Paris, Brussels, Hong Kong, Beijing, Tokyo, Melbourne and Sydney.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye